Affiliation:
1. Central State Medical Academy of the Administrative Department of the President of Russia
2. Central State Medical Academy of the Administrative Department of the President of Russia; Institute for Plastic Surgery and Cosmetology
Abstract
The aim of the study was to study the efficacy and tolerability of the sequential use of the fixed combination of clindamycin + BPO in various clinical situations in real practice. Under our supervision there were 32 patients with mild-to-moderate and severe acne of papulo-pustular acne. Among them, 21 (65.6 %) female patients and 11 (34.4 %) male patients. The patients were divided into two groups: group 1 (teenage acne) of 17 people, group 2 (adult acne) of 15 people. The therapy algorithm included the use of a fixed combination of clindamycin + BPO (Zerkalin Intensive) for 4–5 weeks with a sequential transition to the use of a topical agent with adapalene for 6 months. All patients were prescribed specialized dermatocosmetics on an ongoing basis. As a result of therapy, after a week, there was a significantly significant change in all clinical symptoms of acne. So VAS (comedones) at the end of therapy decreased by 88.9 % (p < 0.01) and by 90.5 % (p < 0.01) in groups 1 and 2, respectively. Similar dynamics was noted in relation to inflammatory elements (papules, pustules). VAS (papules) in groups 1 and 2 decreased by 85.4 % (p < 0.01) and by 88.1 % (p < 0.01), VAS (pustules) – by 100 %. Thus, the use of a fixed combination of clindamycin + BPO causes a high therapeutic effect in relation to all clinical symptoms of acne.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference34 articles.
1. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015; 172 Suppl 1: 3–12. DOI: 10.1111/bjd.13462.
2. Schäfer T, Nienhaus A, Vieluf D, Berger J, Ring J. Epidemiology of acne in the general population: The risk of smoking. Br J Dermatol. 2001; 145 (1): 100–104. DOI: 10.1046/j.1365– 2133.2001.04290.x
3. Kruglova L. S., Talybova A. M., Gryazeva N. V. The effectiveness of the use of a systemic drug based on isotretinoin for various severity of acne. RMJ. Medical review. 2018. No. 4. P. 53–56.
4. Mayslich C, Grange PA, Dupin N. Cutibacterium acnes as an Opportunistic Pathogen: An Update of Its Virulence-Associated Factors. Microorganisms. 2021; 9 (2): 303. Published 2021 Feb 2. DOI: 10.3390/microorganisms9020303.
5. Hwang HJ, Kim JE, Lee KW. Sulforaphene Attenuates Cutibacterium Acnes-Induced Inflammation. J Microbiol Biotechnol. 2022; 32 (11): 1390–1395. DOI: 10.4014/jmb.2209.09051.